Adhera Therapeutics, Inc. Announces Appointment of Zahed Subhan to its Board of Directors
November 08, 2021 at 09:15 am EST
Share
Adhera Therapeutics, Inc. announced the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the Company?s Board of Directors. Dr. Subhan is an international pharmaceutical and biotechnology executive with more than 30 years? experience in the United States, United Kingdom, European Union, and Asia. He is highly proficient in all phases of drug development with expertise in neurology, psychiatry, oncology, cardiovascular, urology and metabolic disease therapeutic areas. Amongst other positions during his career, Dr. Subhan was CEO, NuEvolution A/S, Copenhagen, Denmark (Acquired by Amgen); Chief Business Officer, Gemini Genomics Inc, UK/USA (Acquired by Sequenom Inc.); Head of Business Development and Marketing and European Marketing Director, DuPont Pharmaceuticals (Acquired by Bristol Myers Squibb); Product Manager and New Products Manager, GlaxoSmithKline; and Clinical Research Manager, Sanofi-Aventis. Dr. Subhan is also currently a Clinical/Teaching Professor at Drexel University, PA, US.
Adhera Therapeutics, Inc. is a specialty biotech company. The Company is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The Company's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. It utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Companyâs behalf and under its direct supervision.